ImmunityBio, Inc. (IBRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 60M 120M 180M Q3 '16: 45K Q4 '16: 44K Q1 '17: 49K Q2 '17: 51K Q3 '17: 47K Q4 '17: 45K Q1 '18: 39K Q2 '18: 29K Q3 '18: 52K Q4 '18: 47K Q1 '19: 47K Q2 '19: 60K Q3 '19: 41K Q4 '19: 43K Q1 '20: 203K Q2 '20: 622K Q3 '20: 761K Q4 '20: 773K Q1 '21: 747K Q2 '21: 650K Q3 '21: 565K Q4 '21: 934K Q1 '22: 809K Q2 '22: 505K Q3 '22: 557K Q4 '22: 240K Q1 '23: 586K Q2 '23: 592K Q3 '23: 556K Q4 '23: 622K Q1 '24: 302K Q2 '24: 1.3M Q3 '24: 7.3M Q4 '24: 14.7M Q1 '25: 31.2M Q2 '25: 56.6M Q3 '25: 82.6M Q4 '25: 113.3M Q1 '26: 141M Q2 '26: 165.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 60M 120M 180M Q4 '23: 622K Q1 '24: 302K Q2 '24: 1.3M Q3 '24: 7.3M Q4 '24: 14.7M Q1 '25: 31.2M Q2 '25: 56.4M Q3 '25: 82.2M Q4 '25: 112.5M Q1 '26: 140M Q2 '26: 164.7M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '16: -129.3M Q4 '16: -124.5M Q1 '17: -118.3M Q2 '17: -107.2M Q3 '17: -98.9M Q4 '17: -99.1M Q1 '18: -101.9M Q2 '18: -106.4M Q3 '18: -106.1M Q4 '18: -98.4M Q1 '19: -88.4M Q2 '19: -77.5M Q3 '19: -69.4M Q4 '19: -67.8M Q1 '20: -86.2M Q2 '20: -119.8M Q3 '20: -169.6M Q4 '20: -184.4M Q1 '21: -233.9M Q2 '21: -268.9M Q3 '21: -281.9M Q4 '21: -330.3M Q1 '22: -340M Q2 '22: -333.7M Q3 '22: -345.7M Q4 '22: -351.3M Q1 '23: -366.9M Q2 '23: -372.4M Q3 '23: -361.8M Q4 '23: -362.2M Q1 '24: -345.9M Q2 '24: -360.1M Q3 '24: -360.2M Q4 '24: -344.2M Q1 '25: -313.4M Q2 '25: -285.4M Q3 '25: -260.7M Q4 '25: -256M Q1 '26: -261.4M Q2 '26: -251.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-1.1B -700M -350M 0 350M 700M 1.1B Q3 '16: -123.4M Q4 '16: -120.8M Q1 '17: -114.6M Q2 '17: -104.1M Q3 '17: -96.2M Q4 '17: -96.4M Q1 '18: -99.4M Q2 '18: -103.7M Q3 '18: -103.4M Q4 '18: -96.2M Q1 '19: -86.6M Q2 '19: -75.5M Q3 '19: -67.5M Q4 '19: -65.8M Q1 '20: -84.9M Q2 '20: -119.7M Q3 '20: -169.7M Q4 '20: -186.2M Q1 '21: -228.8M Q2 '21: -265.6M Q3 '21: -287.7M Q4 '21: -346.8M Q1 '22: -370M Q2 '22: -376.3M Q3 '22: -399.6M Q4 '22: -416.6M Q1 '23: -430.1M Q2 '23: -473.4M Q3 '23: -458M Q4 '23: -583.2M Q1 '24: -601M Q2 '24: -597.6M Q3 '24: -587.8M Q4 '24: -413.6M Q1 '25: -409.1M Q2 '25: -367.1M Q3 '25: -348.6M Q4 '25: -351.4M Q1 '26: -854.5M Q2 '26: -992.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 400K 800K 1.2M Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 58K Q2 '25: 194K Q3 '25: 371K Q4 '25: 753K Q1 '26: 933K Q2 '26: 1.1M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '16: -38.8M Q4 '16: -38.6M Q1 '17: -39.8M Q2 '17: -46.4M Q3 '17: -45.9M Q4 '17: -48.8M Q1 '18: -54.2M Q2 '18: -55.5M Q3 '18: -63M Q4 '18: -63.4M Q1 '19: -60.9M Q2 '19: -61.5M Q3 '19: -60.5M Q4 '19: -152.1M Q1 '20: -170.1M Q2 '20: -199.3M Q3 '20: -219.8M Q4 '20: -171.7M Q1 '21: -201.1M Q2 '21: -224.7M Q3 '21: -260.4M Q4 '21: -274.4M Q1 '22: -288.9M Q2 '22: -310.5M Q3 '22: -318.4M Q4 '22: -337.5M Q1 '23: -346.9M Q2 '23: -335.4M Q3 '23: -342.2M Q4 '23: -366.8M Q1 '24: -389.4M Q2 '24: -410M Q3 '24: -421.4M Q4 '24: -391.2M Q1 '25: -370.2M Q2 '25: -349.6M Q3 '25: -319.7M Q4 '25: -304.9M Q1 '26: -294.4M Q2 '26: -281.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '15: -18.3M Q4 '15: -27.5M Q1 '16: -30.1M Q2 '16: -36.5M Q3 '16: -44.9M Q4 '16: -45.2M Q1 '17: -49.8M Q2 '17: -63.5M Q3 '17: -70.6M Q4 '17: -83.6M Q1 '18: -89.4M Q2 '18: -85.1M Q3 '18: -85.5M Q4 '18: -76.5M Q1 '19: -71.3M Q2 '19: -70.3M Q3 '19: -66.1M Q4 '19: -156.4M Q1 '20: -172.6M Q2 '20: -200.9M Q3 '20: -222.9M Q4 '21: -308M Q1 '22: -342.7M Q2 '22: -372.3M Q3 '22: -388.1M Q4 '22: -415.7M Q1 '23: -406.1M Q2 '23: -387.2M Q3 '23: -383.8M Q4 '23: -397.3M Q1 '24: -412.8M Q2 '24: -425.6M Q3 '24: -434.1M Q4 '24: -398.1M Q1 '25: -376.9M Q2 '25: -356.7M Q3 '25: -324.8M Q4 '25: -308.8M Q1 '26: -298.9M Q2 '26: -288.1M Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 400M 800M 1.2B Q3 '20: 381.8M Q1 '21: 382.7M Q2 '21: 384.8M Q3 '21: 391.9M Q1 '22: 397.9M Q2 '22: 398M Q3 '22: 400.1M Q1 '23: 428.4M Q2 '23: 437.5M Q3 '23: 498.4M Q1 '24: 672.8M Q2 '24: 686.9M Q3 '24: 698M Q1 '25: 853.2M Q2 '25: 888.2M Q3 '25: 946.6M Q1 '26: 1B Q2 '26: 1.1B Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.80 -1.20 -0.60 0.00 0.60 1.20 1.80 Q3 '16: -1.51 Q4 '16: -1.47 Q1 '17: -1.39 Q2 '17: -1.27 Q3 '17: -1.18 Q4 '17: -1.20 Q1 '18: -1.25 Q2 '18: -1.31 Q3 '18: -1.31 Q4 '18: -1.22 Q1 '19: -1.09 Q2 '19: -0.91 Q3 '19: -0.77 Q4 '19: -0.71 Q1 '20: -0.59 Q2 '20: -0.56 Q3 '20: -0.57 Q4 '20: -0.59 Q1 '21: -0.70 Q2 '21: -0.79 Q3 '21: -0.84 Q4 '21: -0.89 Q1 '22: -0.94 Q2 '22: -0.95 Q3 '22: -1.01 Q4 '22: -1.05 Q1 '23: -1.06 Q2 '23: -1.14 Q3 '23: -1.05 Q4 '23: -1.16 Q1 '24: -1.09 Q2 '24: -0.97 Q3 '24: -0.92 Q4 '24: -0.63 Q1 '25: -0.58 Q2 '25: -0.48 Q3 '25: -0.41 Q4 '25: -0.38 Q1 '26: -0.85 Q2 '26: -0.97 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.